Baldwin Wealth Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Baldwin Wealth Partners’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300	Closed	-$6.08K	–	820
2022 Q4	$6.08K	Buy	+300	New	+$4.6K	﹤0.01%	645

Baldwin Wealth Partners's OPNT Position: Q1 2023 in Review

Baldwin Wealth Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 300 shares — an estimated $6.08K sold.

Baldwin Wealth Partners first reported a position in OPNT in Q4 2022 and held it in 1 quarter. The position peaked at $6.08K in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Baldwin Wealth Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Baldwin Wealth Partners sold 300 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $6.08K.
Baldwin Wealth Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Baldwin Wealth Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $6.08K in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Baldwin Wealth Partners's 13F filing for Q1 2023, filed 21 Apr 2023.